CMND

0.903

3.56% 0.031

Dopo l'orario di chiusura: .90 -0.003 -0.33%

Clearmind Medicine Inc (CMND)

Panoramica Notizia Cronologia dei prezzi Perché CMND Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.872

Aprire:

$0.8599

Volume 24 ore:

32,036

Relative Volume:

0.14

Capitalizzazione di mercato:

$4.60M

Reddito:

Utile/perdita netta:

$-6.78M

Rapporto P/E:

-0.0211

EPS:

-42.6996

Flusso di cassa netto:

$-4.67M

1 W Prestazione:

+0.34%

1M Prestazione:

-4.14%

6M Prestazione:

-37.72%

1 anno Prestazione:

-42.85%

Intervallo 1D:

$0.85

$0.905

Intervallo di 1 settimana:

$0.85

$0.91

Portata 52W:

$0.80

$2.30

Clearmind Medicine Inc Stock (CMND) Company Profile

Nome

Clearmind Medicine Inc

Settore

Healthcare (1166)

Industria

Biotechnology (655)

Telefono

Indirizzo

Dipendente

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

CMND's Discussions on Twitter

Confronta CMND con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CMND Clearmind Medicine Inc	0.903	4.60M	0	-6.78M	-4.67M	-42.70
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Clearmind Medicine Inc Borsa (CMND) Ultime notizie

Jun 16, 2025

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com

Jun 16, 2025

Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update - Defense World

Jun 16, 2025

Jun 13, 2025

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants - Psychedelic Alpha

Jun 13, 2025

Jun 12, 2025

Clearmind Medicine Inc. (NASDAQ:CMND) Shares Acquired by Citadel Advisors LLC - Defense World

Jun 12, 2025

# Clearmind Medicine hires lobbying firm to advance psychedelic therapy By Investing.com - Investing.com South Africa

Jun 12, 2025

# Clearmind Medicine hires lobbying firm to advance psychedelic therapy - Investing.com Australia

Jun 12, 2025

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics - The Manila Times

Jun 12, 2025

Clearmind Medicine Partners with Leading Government Affairs Firm to Advance Psychedelic Therapeutics - Nasdaq

Jun 12, 2025

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic ... - Bluefield Daily Telegraph

Jun 12, 2025

Jun 05, 2025

Clearmind Medicine Announces Enrollment Of First Patient In Phase I/Iia Clinical Trial For Alcohol Use Disorder Treatment - marketscreener.com

Jun 05, 2025

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment - The Manila Times

Jun 05, 2025

Clearmind Medicine Inc. Begins Phase I/IIa Trial for CMND-100 to Treat Alcohol Use Disorder - Nasdaq

Jun 05, 2025

May 30, 2025

SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq

May 12, 2025

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times

May 12, 2025

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times

May 12, 2025

May 05, 2025

Stocks Under $1 To Watch: $NITO, $SPRC, $PNPNF, $NCNA, $PRSO – Multi-Sectors Momentum Building more inside… | FinancialContent - FinancialContent

May 05, 2025

Apr 28, 2025

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.

Apr 28, 2025

Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment - Investing.com

Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment - Investing.com

Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa

Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India

Apr 25, 2025

Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance

Apr 25, 2025

SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks

Apr 25, 2025

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times

Apr 25, 2025

SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire

Apr 25, 2025

Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq

Apr 25, 2025

Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan

Apr 25, 2025

Apr 23, 2025

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times

Apr 23, 2025

Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq

Apr 23, 2025

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World

Apr 23, 2025

Apr 22, 2025